Jeffrey Larson, PhD, DABT

Jeffrey Larson, PhD, DABT has over 20 years of experience in preclinical and clinical drug development. Jeffrey began their career in 2001 as Senior Director Preclinical Development at Tanox, Inc. where they were responsible for taking monoclonal antibody drugs from the research bench into the clinic. In 2008, they founded Parady Consulting, Inc. and served as President & CEO, offering preclinical development expertise in toxicology, pharmacology and pharmacokinetics. In 2009, they joined NexBio as Associate VP of Nonclinical Development, leading preclinical research and development of anti-influenza biologic, as well as clinical pharmacology and microbiology. From 2010 to 2015, they held Vice President roles at Wildcat Venture Management and Beta Cat Pharmaceuticals (now Iterion Therapeutics). In 2015, they joined Salarius Pharmaceuticals as Vice President, Nonclinical Development. In 2016, they joined Houston Methodist as Board Member, Houston Methodist, Translational Research Institute. In 2018, they joined Iterion Therapeutics as Vice President Of Product Development, overseeing CMC, Regulatory Affairs, Quality and Nonclinical Research and Development. Most recently, in 2020, they joined Tvardi Therapeutics as SVP R&D.

Jeffrey Larson holds a Ph.D. in Pharmacology/Toxicology from Washington State University, which they obtained in 1990. Prior to that, they earned a BA in Environmental Science from Minot State University in 1986. Jeffrey also holds a DABT certification from the American Board of Toxicology, Inc., which they obtained in January 1994.